Soren Giese – General Manager, Amgen Italy
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Contact
Amgen
Via Tazzoli, 6
20154 – Milano Italia
Tel.: 0039 02 6241121
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
Having successfully accomplished a four-year turnaround exercise and with a fresh capital injection from a leading Italian PE firm, SIFI executive chairman Fabrizio Chines has ambitious growth objectives for the…
Simona Falciai, General Manager of Shionogi, provides insights into the launch of the Italian affiliate, how the company is catering to a key unmet medical need with Ospemifene, the first…
Outspoken Italian Managing Director of Israeli-based Teva, Hubert Puech d’Alissac, talks about his passion for social responsibility, adapting to the new realities of patient care in the digital age, and…
Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not…
The president of Chiesi explains how innovation and a strong focus on quality have led to outstanding growth and have established the Italian family-run business as a significant pharma player…
Dr. Osvaldo Ponchiroli, CEO of OP Pharma, discusses the expertise his company can offer to help navigate Italy’s regulatory environment, the outlook for medium-sized generics companies in Italy and OP’s…
Family-owned Laboratori Baldacci is something of a rare breed in an industry dominated by multinational players. The senior research manager discusses the history of the company as well as how…
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Now part of the Sanofi group, as SanofiGenzyme, it benefits from the reach and resources of…
Alexander Zehnder discusses Sanofi’s sizable contribution to the Italian economy, manufacturing in Italy, and the country’s labyrinthine drug approval processes. What have been your main areas of focus and priorities since your appointment…
Country Manager Giovanna Labbate talks how Gedeon Richter aims to become the point of reference for women’s health in Italy, the successful launch of ESMYA, and the establishment of the…
Mr. Aldo Braca discusses the competitive CDMO landscape in Italy, the importance of nurturing a community of employees, and the optimistic growth trend for the company powered by investment and…
Manlio Florenzano discusses Sandoz’s engagement in Italy and the role of generics firms in contributing to a more affordable and sustainable Italian healthcare system. Can you please start by introducing…
See our Cookie Privacy Policy Here
